Fulcrum Therapeutics Inc (FULC)
$7.25
+0.41
(+5.99%)▲
Insights on Fulcrum Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 759.0K → 871.0K (in $), with an average increase of 12.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -21.61M → -24.75M (in $), with an average decrease of 4.7% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 275.0%
Performance
- $6.85$7.26$7.25
5.52%
Downside
Day's Volatility :5.65%
Upside
0.14%
- $2.43$13.70$7.25
66.48%
Downside
52 Weeks Volatility :82.26%
Upside
47.08%
Returns
| Period | Fulcrum Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 7.89% | -0.4% | 0.0% |
6 Months | 105.38% | 9.6% | 0.0% |
1 Year | 173.58% | 3.9% | -1.3% |
3 Years | -36.68% | 12.8% | -22.1% |
Highlights
Market Capitalization | 423.6M |
Book Value | $3.8 |
Earnings Per Share (EPS) | -1.59 |
Wall Street Target Price | 13.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -3213.78% |
Return On Assets TTM | -28.56% |
Return On Equity TTM | -44.84% |
Revenue TTM | 2.8M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 27.200000000000003% |
Gross Profit TTM | -70.4M |
EBITDA | -108.5M |
Diluted Eps TTM | -1.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.75 |
EPS Estimate Next Year | -1.71 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.44 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 82.76%
Technicals Summary
Sell
Neutral
Buy
Fulcrum Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Fulcrum Therapeutics Inc | -23.12% | 105.38% | 173.58% | -36.68% | -46.3% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Fulcrum Therapeutics Inc | NA | NA | NA | -1.75 | -0.45 | -0.29 | NA | 3.8 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Fulcrum Therapeutics Inc | Buy | $423.6M | -46.3% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
18.74%FMR Inc
9.18%Suvretta Capital Management, LLC
8.91%RTW INVESTMENTS, LLC
8.83%COWEN AND COMPANY, LLC
5.61%Vanguard Group Inc
4.07%
Corporate Announcements
Fulcrum Therapeutics Inc Earnings
Fulcrum Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Organization | Fulcrum Therapeutics Inc |
Employees | 76 |
CEO | Mr. Alexander C. Sapir |
Industry | Health Technology |
